Resource use in patients with psoriasis after the introduction of biologics in Sweden

Acta Dermato-Venereologica

Volumn 95, Issue 2, 2015, Pages 156-161

  Norlin, Jenny M ^a,b   Carlsson, Katarina Steen ^b,c   Persson, Ulf ^b,d   Schmitt Egenolf, Marcus ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^c Health Economics unit Department of Clinical Sciences   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Biologics; Cost of illness; Productivity loss; Psoriasis

Indexed keywords

BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; DISABILITY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MEDICAL SPECIALIST; MIDDLE AGED; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSORIASIS; SWEDEN; ABSENTEEISM; AGED; AMBULATORY CARE; CASE CONTROL STUDY; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; HEALTH CARE PLANNING; INSURANCE; PATIENT REFERRAL; PRODUCTIVITY; REGISTER; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UTILIZATION;

ABSENTEEISM; ADULT; AGED; BIOLOGICAL PRODUCTS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; DERMATOLOGIC AGENTS; DRUG COSTS; EFFICIENCY; FEMALE; HEALTH RESOURCES; HUMANS; INSURANCE, DISABILITY; MALE; MIDDLE AGED; MODELS, ECONOMIC; OFFICE VISITS; PSORIASIS; REFERRAL AND CONSULTATION; REGISTRIES; SICK LEAVE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928235405     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1895     Document Type: Article

References (34)

1. Lomholt G. Prevalence of skin disease in a population: A census study from the Faroe islands. Dan Med Bull 1964; 11: 1–7.
2. Prey S, Paul C, Bronsard V, Puzenat E, Gourraud PA, Aractingi S, et al. Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 Suppl 2: 31–35.
3. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108–113.
4. Berger K, Ehlken B, Kugland B, Augustin M. Cost-ofillness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511–518.
5. Sohn S, Schoeffski O, Prinz J, Reich K, Schubert E, Waldorf K, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137–144.
6. Carrascosa JM, Pujol R, Dauden E, Hernanz-Hermosa JM, Bordas X, Smandia JA, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). J Eur Acad Dermatol Venereol 2006; 20: 840–845.
7. Colombo G, Altomare G, Peris K, Martini P, Quarta G, Congedo M, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008; 4: 559–568.
8. Navarini AA, Laffitte E, Conrad C, Piffaretti P, Brock E, Ruckdaeschel S, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010; 140: 85–91.
9. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010; 162: 1324–1329.
10. Ghatnekar O, Ljungberg A, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden – a cross-sectional study. Eur J Dermatol 2012; 22: 238–245.
11. Ekelund M, Mallbris L, Qvitzau S, Stenberg B. A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis. Acta Derm Venereol 2013; 93: 684–688.
12. Barzi S, Befrits G, Bergman B, Bruchfeld J, Ettarp L, Flytström I, et al. [Drug treatment of Psoriasis – new recommendation]. Information from The Medical Products Agency. 2011 (in Swedish).
13. Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20: 1929–1936.
14. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008; 59: 772–780.
15. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846–850.
16. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17–27.
17. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–1741.
18. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic antiinflammatory drugs: a Danish real-world cohort study. J Int Med 2013; 273: 197–204.
19. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225–230.
20. Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011; 25: 157–163.
21. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice. Dermatology 2012; 225: 326–332.
22. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–407.
23. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383–392.
24. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236–244.
25. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaquetype psoriasis: A multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366–372.
26. Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol 2012; 51: 1432–1440.
27. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013; 7: 199–205.
28. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, et al. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatologi Treat 2011; 22: 337–347.
29. Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting. Appl Health Econ Health Policy 2012; 10: 343–353.
30. Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 66: e67–e76.
31. LFN. [Pharmaceutical Benefits Board’s general advice.]: LFNAR 2003; 2: 2003 (in Swedish).
32. ekonomifakta.se. [Payroll fees.] Available from: http:// wwwekonomifaktase/sv/Fakta/Arbetsmarknad/Arbetsgivaravgift/ Sociala-avgifter. [cited 2013 Nov] (in Swedish).
33. NBHW. The National Board for Health and Welfare [Quality and content of the patient record - discharges from inpatient care 1964–2007 and visits to specialist outpatient care (excluding primary care visits) 1997–2007.] (in Swedish).
34. Neovius M. [Rheumatoid arthritis, biological treatment and lost working days - example of using the Swedish health registries. Report from SNS research program. The value of new drugs.] 2013 (in Swedish).